Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lineage Cell Therapeutics Inc (LCTX)

Lineage Cell Therapeutics Inc (LCTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 396,164
  • Shares Outstanding, K 230,328
  • Annual Sales, $ 9,500 K
  • Annual Income, $ -18,610 K
  • EBIT $ -20 M
  • EBITDA $ -20 M
  • 60-Month Beta 1.78
  • Price/Sales 42.19
  • Price/Cash Flow N/A
  • Price/Book 19.11

Options Overview Details

View History
  • Implied Volatility 176.64% (-0.71%)
  • Historical Volatility 64.86%
  • IV Percentile 43%
  • IV Rank 10.94%
  • IV High 863.26% on 04/17/25
  • IV Low 92.31% on 08/18/25
  • Expected Move (DTE 12) 0.2550 (14.83%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 22
  • Volume Avg (30-Day) 368
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 20,465
  • Open Int (30-Day) 21,010
  • Expected Range 1.4650 to 1.9750

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.07
  • Number of Estimates 3
  • High Estimate -0.02
  • Low Estimate -0.14
  • Prior Year -0.01
  • Growth Rate Est. (year over year) -600.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5300 +12.42%
on 11/07/25
1.9900 -13.57%
on 11/13/25
-0.1000 (-5.49%)
since 11/05/25
3-Month
1.2000 +43.33%
on 09/10/25
2.0900 -17.70%
on 11/03/25
+0.5000 (+40.98%)
since 09/05/25
52-Week
0.3651 +371.10%
on 04/09/25
2.0900 -17.70%
on 11/03/25
+1.1488 (+201.12%)
since 12/05/24

Most Recent Stories

More News
Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Positive RG6501 (OpRegen ® ) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 ...

LCTX : 1.7200 (-1.15%)
Lineage Cell Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic, or “off the shelf”, cell therapies for serious medical conditions,...

LCTX : 1.7200 (-1.15%)
Anti-Aging Market Surges as $101M Competition Drives Demographic Revolution

Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – The global longevity biotech market exploded from $27.15 billion in 2024 toward $46.61 billion by 2033...

LXRX : 1.4000 (-1.41%)
AVAI : 0.2875 (-2.58%)
LCTX : 1.7200 (-1.15%)
ARQT : 31.20 (+0.13%)
AMGN : 329.89 (-3.02%)
Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes

Initial Program Focus Will Be On Addressing Manufacturing Scale

LCTX : 1.7200 (-1.15%)
Lineage Cell Therapeutics to Present at September 2025 Investor Conferences

H.C. Wainwright 27 th Annual Global Investment Conference Presentation on September 8, 2025 ...

LCTX : 1.7200 (-1.15%)
Lineage Announces Research Collaboration With William Demant Invest to Develop ReSonance™ (ANP1) for Hearing Loss

Three-year term intended to advance preclinical development of ReSonance Up to $12 million of development...

LCTX : 1.7200 (-1.15%)
Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Positive RG6501 (OpRegen ® ) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 ...

LCTX : 1.7200 (-1.15%)
Lineage Cell Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced...

LCTX : 1.7200 (-1.15%)
Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury

Successful First-In-Human Use of New Parenchymal Spinal Delivery System First-ever Administration of OPC1...

LCTX : 1.7200 (-1.15%)
Insider Purchase: President and CEO of $LCTX (LCTX) Buys 40,000 Shares

Brian M Culley, the President and CEO of $LCTX ($LCTX), bought 40,000 shares of the company on 11-21-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased...

LCTX : 1.7200 (-1.15%)

Business Summary

Lineage Cell Therapeutics Inc. is a clinical-stage biotechnology company. It focuses on developing and commercializing therapies for the treatment of degenerative diseases primarily in the United States and internationally. The company's lead product candidates include OpRegen, OPC1 and VAC2 which are...

See More

Key Turning Points

3rd Resistance Point 1.7967
2nd Resistance Point 1.7733
1st Resistance Point 1.7467
Last Price 1.7200
1st Support Level 1.6967
2nd Support Level 1.6733
3rd Support Level 1.6467

See More

52-Week High 2.0900
Last Price 1.7200
Fibonacci 61.8% 1.4311
Fibonacci 50% 1.2275
Fibonacci 38.2% 1.0240
52-Week Low 0.3651

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar